Physician profile
Harold E Ayers
NPI 1780783670
$5,275.52
in general payments reported to CMS, 2019-2025
39 companies · $710 in 2025
The $710 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $444 · 2020: $376 · 2021: $673 · 2022: $1,698 · 2023: $786 · 2024: $589 · 2025: $710.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,085.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,085.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,470.85 | 2021-2025 | Qulipta, Ubrelvy, Linzess |
| Glaxosmithkline, LLC. | $503.18 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $321.37 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $286.45 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Amgen INC. | $261.51 | 2019-2025 | Repatha, Otezla, Repatha |
| Sanofi-Aventis U.S. LLC | $255.72 | 2019-2023 | |
| Lilly USA, LLC | $235.38 | 2022-2024 | Mounjaro, Jardiance, Zepbound |
| Novartis Pharmaceuticals Corporation | $209.55 | 2020-2023 | |
| Astrazeneca Pharmaceuticals Lp | $160.31 | 2019-2025 | Tezspire, Farxiga |
| Astellas Pharma US INC | $160.24 | 2023-2024 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.00 | 2019-2025 | Jardiance |
| Pfizer INC. | $144.79 | 2019-2025 | |
| Abbott Laboratories | $128.68 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $98.77 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $92.98 | 2020-2023 | Eliquis |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harold Ayers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.